Researchers identified that amlodipine, a widely prescribed calcium channel blocker for hypertension, demonstrates significant anti-tumor activity against hepatocellular carcinoma cells. The drug appears to work by disrupting cellular calcium signaling pathways that cancer cells rely on for proliferation and survival, while simultaneously enhancing the effectiveness of existing chemotherapy agents when used in combination. This discovery represents a compelling example of drug repurposing, where established medications find new therapeutic applications. Amlodipine's well-documented safety profile from decades of cardiovascular use could accelerate clinical translation compared to developing novel compounds from scratch. The financial implications are substantial—generic amlodipine costs pennies per dose versus thousands of dollars for targeted liver cancer therapies like sorafenib. However, the research appears to be in early preclinical stages, likely using cell culture or animal models rather than human patients. Liver cancer remains notoriously difficult to treat, with five-year survival rates below 20 percent for advanced cases. While promising, this finding requires validation through rigorous clinical trials to establish proper dosing, efficacy, and safety specifically for oncological applications rather than cardiovascular use.